BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q2 2026 results for the quarter ended June 30, 2026. It said it is preparing to start the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, planning about 200 patients. Cash was about $0.2M vs $1.03M a year earlier, with Q2 net loss about $3.9M. The company appointed Peter J. Pitts as Executive Chairman and raised about $400k in private placements.
How this was made
The 30-second read
Why it matters
The article combines (1) operational readiness claims for ENDURANCE enrollment under SPA, (2) an executive leadership change aimed at regulatory and partnership execution, and (3) updated financials showing a sharp cash decline and higher operating costs.
Market read
Traders may reprice near-term probability of ENDURANCE launch and the financing/dilution risk implied by the reduced cash balance.
What to watch
The release does not provide enrollment start timing, trial site readiness, or any new financing amount beyond small private placements, leaving execution and funding uncertainty largely unresolved.
Background
BrainStorm Cell Therapeutics is advancing NurOwn (MSC-NTF) for ALS and is preparing to initiate a Phase 3b ENDURANCE study under an FDA Special Protocol Assessment.
Ticker impact
BrainStorm reports Q2 2026 cash of about $0.2M and says it is completing work to open the Phase 3b ENDURANCE NurOwn enrollment under FDA SPA.
Likely modest positive bias on SPA readiness and leadership credibility, offset by weak cash balance and higher dilution risk.
The release provides concrete operational milestones (ENDURANCE readiness, SPA) and new financial datapoints (cash down sharply, higher G&A), which can shift probability-weighted timelines and financing expectations.
Market effects
Highlights continued FDA SPA use in ALS cell-therapy development, reinforcing a regulatory pathway narrative for regenerative medicine peers.
Limited, OTC microcap-specific sentiment spillover to small-cap biotech investors.
Low; primarily US regulatory and ALS program execution.
Counterpoint
SPA and leadership appointments may not reduce the core bottleneck: the company still has very limited cash, so dilution or delays could dominate near-term outcomes.
Key entities
- companyBrainStorm Cell Therapeutics Inc.
OTCQB-listed developer of NurOwn adult stem cell therapeutics for ALS.
- product_programNurOwn (MSC-NTF)
Autologous MSC-derived neurotrophic factor-secreting cell therapy in ALS Phase 3b ENDURANCE preparation.
- regulatoryFDA Special Protocol Assessment (SPA)
FDA-agreed protocol framework intended to support a future BLA for ENDURANCE.
- executivePeter J. Pitts
Appointed Executive Chairman to lead regulatory, operational, partnership, and capital-markets initiatives.
